Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

bstantially reduced at the 100 mg/m2 dose, where 5 of 24 patients (21%) had grade 3 or 4 thrombocytopenia.

Small cell lung cancer metastasizes frequently to the bone marrow and the brain. Eighteen patients on the study presented with brain metastases. Of these patients, 3 achieved a partial systemic response and 3 demonstrated stable disease.

Dr. F. Anthony Greco, Director of the Sarah Cannon Research Institute in Nashville, Tennessee, commented, "Cloretazine(R) (VNP40101M) has impressive activity in small cell lung cancer in the second-line setting, including activity against brain metastases, and further evaluation is warranted."

Ann Cahill, Vion's Vice President, Clinical Development, said, "Our solid tumor clinical development plan for Cloretazine(R) (VNP40101M), which includes our Phase II trial in small cell lung cancer, and the recently completed trials in adult and pediatric brain tumors, is an important part of the overall clinical development program for this novel alkylating agent." Ms. Cahill added, "We are encouraged by this promising data in small cell lung cancer."

Additional data from a Phase I trial conducted by the Pediatric Brain Tumor Consortium of Cloretazine(R) (VNP40101M) as a single agent in pediatric brain tumors will be presented at the ASCO Annual Meeting in poster U1 in S Hall A2 at the McCormick Place Convention Center on Monday, June 4, 2007 from 1 to 5 p.m.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer is also underway
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/29/2015)... ALBANY, New York , July 29, 2015 /PRNewswire/ ... published by Transparency Market Research " Active Pharmaceutical Ingredients ... Trends and Forecast 2014 - 2020 " the global ... billion in 2013 and is anticipated to reach USD ... 6.5% during the forecast period from 2014 to 2020. ...
(Date:7/29/2015)... 24, 2015 Research and Markets ( ... "Global Wound Care Markets (Twelve Country Analysis: ... Canada, China, India, Brazil, Australia, South Korea)" ... report provides a competitive market summary. The wound ... product offerings and product maturity. Several of the ...
(Date:7/29/2015)... YORK , July 29, 2015 /PRNewswire/ ... a new research report "Global Industry Insight: ... to 2020" with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... http://photos.prnewswire.com/prnh/20150727/756778 ) Microfluidic devices  ...
Breaking Medicine Technology:Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 2Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 3Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 4Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 5Global Wound Care Markets 2015 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5
... Feb. 9, 2012 Former employees of Omnicare, Inc., ... care for seniors, claim that they have been unlawfully underpaid ... filed January 26th in U.S. District Court for the ... et al ., Case Number 8:12-cv-00169) seeks relief under ...
... 2012   Resource Anesthesia , an anesthesia contract management ... locations to its management portfolio. Phil Haynie, ... that the company has added the following facilities to ... of Washington -- Hadley, 4601 Martin Luther King Jr. ...
Cached Medicine Technology:A Full Day's Pay for a Full Day's Work 2Resource Anesthesia Adds Locations Under Management, Announces Addition of HealthStream LearningCenter® 2
(Date:7/29/2015)... ... ... " Core Organizer ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... anyone get organized. , Wouldn’t it be great if everyone could be a little ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... autism. Parents, educators and service providers of children living with autism will converge ... serve the growing demographic. , The National Autism Conference will be held ...
(Date:7/29/2015)... ... 2015 , ... According to The Spirits Business on July 16th, ... for stimulating and perpetuating alcohol use disorders. Humans have the same gene, which is ... academy of Sciences, and has given researchers inklings to explore Rsu1 in humans to ...
(Date:7/29/2015)... ... July 29, 2015 , ... With a new ... up with Stillwaters Cancer Support Services and announced a new charity campaign to ... family counseling, support groups, workshops and educational programs at no charge. Scott ...
(Date:7/29/2015)... ... July 29, 2015 , ... Wedding season is in full swing, which means bridal beauty ... of looking good on the big day. Every bride wants to look and feel beautiful, ... , According to a recent study by the American Academy of ...
Breaking Medicine News(10 mins):Health News:Get More Organized with the Core Organizer App 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3
... France, Sunday 15 May 2011: The European Society of Cardiology ... the evaluation and approval of medical devices. The call ... European Heart Journal reporting on a conference ... input of medical experts in developing medical device policy. "The ...
... known by the brand name Celebrex, triggers liver cancer cell ... makes those cells commit suicide, according to a new study. ... each of two chemotherapy drugs killed more liver cancer cells ... on its own. "Each chemotherapy drug alone will reduce ...
... (May 16, 2011)Today,s anticancer drugs often work wonders against ... of such drugs, and treatment fails. Medical researchers would ... first they must understand why and how it happens. ... one protein, Abcc10 (also known as Mrp7), as being ...
... - Despite recent concerns that medications for attention deficit ... events in children and adolescents, an observational study conducted ... Medicine and HealthCore Inc. finds they are no more ... those who do not take the drugs. The findings, ...
... ATS 2011, DENVER The six-minute walking distance test ... tolerate exercise and physical activity, is an effective tool ... pulmonary disease (COPD), according to a three-year global study ... The study will be presented at the ...
... of lung cells to divide may play a role in ... obstructive pulmonary disease (COPD), according to a study conducted by ... the ATS 2011 International Conference in Denver. "We found ... impaired ability to divide, or had lost their ability to ...
Cached Medicine News:Health News:ESC Policy Conference makes recommendations for new EU medical device legislation 2Health News:ESC Policy Conference makes recommendations for new EU medical device legislation 3Health News:ESC Policy Conference makes recommendations for new EU medical device legislation 4Health News:Common anti-inflammatory coaxes liver cancer cells to commit suicide 2Health News:Common anti-inflammatory coaxes liver cancer cells to commit suicide 3Health News:Common anti-inflammatory coaxes liver cancer cells to commit suicide 4Health News:Abcc10 may be effective in extending the effectiveness of anticancer drugs 2Health News:Abcc10 may be effective in extending the effectiveness of anticancer drugs 3Health News:No increase in severe cardiovascular events for children, adolescents taking ADHD medications 2Health News:'Walking distance' test an accurate indicator of disease severity in patients with COPD 2Health News:Cell division abnormality contributes to inflammation in COPD 2
... These dual pressure sensor ... sampling/slow-speed injection, slow-speed injection/guide wire, ... model SPC-784A for high-speed injection ... side openings and an open-end ...
... Mikro-Tip Pressure Catheters; Millar manufactures and ... sensor catheters for simultaneous high fidelity ... for measuring pressure gradients across a ... vascular stenosis. The catheters are made ...
... The XTD Thrombectomy catheter is a mechanical ... thrombus from occluded hemodialysis access grafts. The ... consists of a rotatable, spiral shaft which ... a flexible, distal curved tip. In use, ...
... These catheters are indicated ... soft emboli and thrombi from ... These catheters may also be ... blood vessels, infusion of fluids, ...
Medicine Products: